Americans’ medicines are increasingly manufactured in developing countries, where oversight is lower than in the US, according to a white paper by the Pew Health Group. The US Food and Drug Administration (FDA) estimates 40% of finished drugs and 80% of active ingredients and bulk chemicals used in US drugs come from overseas.
The white paper, “After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs,” finds that increased outsourcing of manufacturing, a complex and globalized supply chain and criminal actors create the potential for counterfeit or substandard medicines to enter the supply chain and reach patients. For economic reasons, the migration of manufacturing abroad is likely to continue. At the same time, industry and government agencies have failed to adapt to the changing environment.
“Today’s prescriptions are being produced under last century’s oversight,” said Allan Coukell, director of medical programs at the Pew Health Group. “Compared with a decade ago, pharmaceutical supply lines stretch around the world and out to a complex web of suppliers.
Regulators and industry must modernize supervision of the manufacturing process to ensure the drugs we consume are safe. The “After Heparin” white paper indentifies links in the supply chain that government and business should strengthen,” Coukell added.
Substandard or adulterated pharmaceutical materials from abroad have entered the US on multiple occasions. Additionally, the risks of domestic counterfeiting and diversion of stolen drugs are well documented. The white paper presents several case studies, including incidents involving heparin, a blood thinner adulterated during its manufacture in China, counterfeit vials of the anemia drug Epogen and stolen vials of insulin to illustrate the threats and suggest solutions.
“After Heparin” is based on public information, including FDA documents, US Government Accountability Office reports, congressional testimony, peer-reviewed journals and interviews with more than 50 supply chain experts and stakeholders. The findings and recommendations were discussed during a two-day convening on the white paper that included a diverse group of industry representatives, ranging from ingredient manufacturers to community pharmacists.
SOURCE: Press Release, Pew Prescription Project.